Emily Mullin, who had been reporting on biotech for Medium’s OneZero publication, is among those who have taken its buyout offer.
“I’m grateful to have had the opportunity to pursue meaningful stories about biotechnology and society over the past two years,” she wrote on Twitter.
Emily Mullin
Mullen was previously a freelance writer who has had bylines in The Washington Post, The Wall Street Journal, Scientific American, National Geographic, The Atlantic, Science, Quartz, Pacific Standard, and The Baltimore Sun, among others.
Her areas of interest include gene therapy, CRISPR, consumer genetics, reproductive technology, brain implants, regenerative medicine, biohacking, and AI in medicine.
She has also worked as associate editor for biomedicine at MIT Technology Review, where she earned a Newsbrief Award from the D.C. Science Writers Association.
She earned her bachelor’s degree in journalism at Ohio University and a master’s in science writing from Johns Hopkins University.
